ANALGESIC NEPHROPATHY

Year 2019, Volume: 2 Issue: 1, 55 - 67, 11.09.2019

Gönül Şahin Sonia Sanajou Hananeh Kordbacheh

Abstract

Non-steroidal anti-inflammatory
drugs (NSAIDs), which are easily accessible, inexpensive and have many
therapeutic effects, are used frequently and in large quantities by every age
group of patients. NSAIDs reversibly inhibit cyclooxygenase
enzymes at various degrees and they have the same action and
toxicity mechanism. These groups of drugs can cause damage in many organs when
there used at high dose and for a long-time period. Analgesic nephropathy is
one of the prominent side effects of NSAIDs which damage kidneys. The present review focused on
renal toxic mechanisms induced by NSAIDs. The geriatric group which is the
most vulnerable group to misusage of NSAIDs should be well informed and
monitored by healthcare professionals to decrease the risk of adverse effects related
to NSAIDs. 

Keywords

Analgesic, Analgesic Nephropathy, cortical tubulointerstitial nephritis, non-steroidal anti-inflammatory drugs, renal papillary necrosis

References

• Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, Knaggs R, Martin D, Sampson L, Schofield P, British Geriatric Society (2013). Guidance on the management of pain in older people. Age Ageing 42:1–57.
• American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons (2009). Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 57(8):1331–1346.
• Bluemle LW Jr, Goldberg M (1969). Renal accumulation of salicylate and phenacetin: possible mechanisms in the nephropathy of analgesic abuse. J Clin Invest 47(11):2507–2514.
• Borda IT, Koff RS (1992). In: NSAIDs : A profile of adverse effects. Philadelphia: Hanley & Belfus;. pp. 240-256.
• Buer JK. (2014). Origins and impact of the term ‘NSAID’. Inflammopharmacology 22(5):263–267.
• Chang S, Mathew T, McDonald S (2008). Analgesic nephrop- athy and renal replacement therapy in Australia: Trends, comorbidities and outcomes. Clin J Am Soc Nephrol 3:768–776.
• Cove-Smith JR (1981). Analgesic nephropathy in the United Kingdom: incidence, clinical features and pathogenesis. J Clin Pathol 34:1255–1260.
• DeWitt DL, Meade EA, Smith WL (1993). PGH synthase isoenzyme selectivity: The potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 95(2):40–44.
• De Broe M, Elseviers M (2009). Over the counter analgesic use. J Am Soc Nephrol 20:2098–2103.
• De Broe Marc E, Elseviers Momique M (1998). Analgesic nephropathy. N Engl J Med 338:446–452.
• Dunn MJ, Scharschmidt L, Zambraski E (1984). Mechanisms of the nephrotoxicity of non-steroidal anti-inflammatory drugs. Archives of Toxicology. Supplement. Arch Toxicol Suppl 7:328–337.
• Emkey RD, Mills JA (1982). Aspirin and Analgesic Nephropathy. JAMA 247(1):55.
• Fischer S, Weber PC (1984). Prostaglandin l3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307:165-8.
• Gault M, Wilson D (1978). Analgesic nephropathy in Canada: Clinical syndrome, management and outcome. Kidney Int 13:58–63.
• Hao CM, Yull F, Blackwell T, Kömhoff M, Davis LS, Breyer MD (2000). Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J Clin Invest 106:973–982.
• Harris RC (2003). Interactions between COX-2 and the renin-angiotensin system in the kidney. Acta Physiol Scand 177:423-427.
• Harirforoosh S, Jamali F (2009). Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 8(6):669–681.
• Hanna VS, Hafez EAA (2018). Synopsis of arachidonic acid metabolism: A review. J Adv Res 11:23–32.
• Hawkey CJ (2001). COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 15(5), 801–820.
• Hilário MOE, Terreri MT, Len CA (2006). Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors. J Pediatr (Rio J) 82(8):206–212.
• Hunter LJ, Wood DM, Dargan PI (2011). The patterns of toxicity and management of acute nonsteroidal anti-inflammatory drug (NSAID) overdose. Open Access Emerg Med 6(3):39-48.
• Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y (2015). Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. Biochim Biophys Acta 4:414–421.
• Lote CJ, Haylor J (1989). Eicosanoids in renal function. Prostaglandins Leukot Essent Fatty Acids 36(4):203–217.
• Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Patrono C (1997). SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 283(3):1059–1068.
• Murray RM, Lawson DH, Linton AL (1971). Analgesic nephropathy: clinical syndrome and prognosis. Br Med J 1(5747):479–482.
• Nanra RS, Stuart-Taylor J, de Leon AH, White KH (1978). Analgesic nephropathy: etiology, clinical syndrome, and clinicopathologic correlations in Australia. Kidney Int 13(1):79-92.
• Noels L, Elseviers M, De Broe M. Impact of legislative measures on the sales of analgesics and the subse- quent prevalence of analgesic nephropathy: A com- parative study in France, Sweden and Belgium. Nephrol Dial Transplant 10:167–174.
• Palaniyappan L, Insole L, Ferrier N (2009). Combining antidepressants: a review of evidence. Advances in Psychiatric Treatment 15(2): 90–99.
• Pintér I, Mátyus J, Czégány Z, Harsányi J, Homoki M, Kassai M, Kiss E, Kiss I, Ladányi E, Locsey L, Major L, Misz M, Nagy L, Polner K, Rédl J, Solt I, Tichy B, Török M, Varga G, Wagner G, Wórum I, Zsoldos B, Pótó L, Dérczy K, Wittmann I, Nagy J (2004). Analgesic nephrop- athy in Hungary: The HANS study. Nephrol Dial Transplant 19:840–843.
• Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M (1999). Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66:76–84.
• Sakai M, Kakutani S, Horikawa C, Tokuda H, Kawashima H, Shibata H, Okubo H, Sasaki S (2012). Arachidonic acid and cancer risk: a systematic review of observational studies. BMC Cancer 12:606.
• Serhan CN, Levy B (2003). Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc Natl Acad Sci USA 100(15):8609–8611.
• Schrier RW, Coffman TM, Falk RJ, Molitoris BA, Neilson EG (2013). Schrier’s Diseases of the Kidney. 9th ed, Wolters Kluwer, Baltimore.
• Stichtenoth DO, Wagner B, Frolich JC (1998). Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med 46:290-296.
• Waddington F, Naunton M, Thomas J (2014). Paracetamol and analgesic nephropathy: Are you kidneying me?. Int Med Case Rep J 8:1–5.
• Wlodawer P, Samuelsson B (1973). On the organization and mechanism of prostaglandin synthetase. J Biol Chem 248(16):5673–5678.
• Zarghi A, Arfaei S (2011). Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res IJPR 10(4):655–683.